Compounded semaglutide: what it is and how it differs from branded
Same active ingredient, different finished product, different regulatory status.
TL;DR
- Compounded semaglutide is a prescription medication prepared by a state-licensed 503A compounding pharmacy using semaglutide active pharmaceutical ingredient.
- The active molecule is the same as in branded products like Ozempic and Wegovy. The finished compounded version is not FDA-approved as a finished drug product.
- Access is governed by an evolving regulatory and legal landscape; compounded GLP-1 medications are currently the subject of ongoing litigation.
What it is
Compounded semaglutide is a prescription medication that contains semaglutide as its active ingredient. The compounded version is prepared by a 503A compounding pharmacy — a state-licensed facility that mixes prescriptions to order under a clinician’s prescription (FDA — Compounding and FDA: Q&A). The branded versions, Ozempic and Wegovy, are FDA-approved finished products manufactured by Novo Nordisk. The compounded version is not itself FDA-approved as a finished drug product, though the active pharmaceutical ingredient (in plain English: the raw drug substance) used by the pharmacy is sourced from FDA-approved suppliers.
Imagine a kitchen analogy. The branded product is a sealed, labeled jar from a major manufacturer. The compounded product is the same core ingredient mixed by a licensed pharmacy to a specific prescription. The contents share a name; the packaging, the formulation, and the regulatory status do not.
How it works
Semaglutide is a GLP-1 receptor agonist (in plain English: a molecule that switches on the same receptor as GLP-1, a gut hormone the body releases after a meal). When the receptor is activated, the body slows stomach emptying, increases the sense of fullness, and releases more insulin in response to food (Drucker, Cell Metabolism, 2018). The mechanism is the same regardless of whether the molecule is in a branded or compounded preparation.
Who asks about it
People come to this question through one of two routes: cost (compounded versions are typically priced lower than branded) and access (compounded routes have been used during branded shortages). The first honest answer is that “compounded” is a regulatory category, not a quality grade.
What the research says
The major clinical trials of semaglutide — including the STEP and SELECT programs — were conducted with the FDA-approved branded product. Those trials are the published evidence base for the molecule. Compounded semaglutide, as a finished compounded product, has not been tested in equivalent large-scale randomized trials.
What to know before considering it
Compounded GLP-1 medications are the subject of ongoing litigation (Novo Nordisk v. Hims & Hers, February 2026). Any access requires a valid prescription following a licensed clinician evaluation. Side-effect profile, dosing, and contraindications are covered in dedicated posts.
The Halftime POV
“Compounded” is a regulatory framework, not a marketing claim. The honest way to talk about compounded semaglutide is to describe what it is, who can prescribe it, and what the published evidence covers — and to say plainly what it is not.
Related reading:
- GLP-1: what this gut hormone actually does
- Novo Nordisk v. Hims & Hers: the compounded GLP-1 case
- 503A vs 503B compounding pharmacies explained
FAQ
Q: What is compounded semaglutide? A: Compounded semaglutide is a prescription medication prepared by a state-licensed 503A compounding pharmacy from FDA-approved active pharmaceutical ingredient. The compounded version is not itself FDA-approved as a finished drug product. It is dispensed only with a valid prescription following a clinician evaluation.
Q: Is compounded semaglutide the same as Ozempic or Wegovy? A: The active ingredient is the same molecule, semaglutide. The finished products are different. Ozempic and Wegovy are FDA-approved branded products manufactured by Novo Nordisk. Compounded semaglutide is prepared by a 503A pharmacy in a different formulation and is not FDA-approved as a finished product.
Q: Is compounded semaglutide legal in 2026? A: Compounded GLP-1 medications are the subject of ongoing litigation and evolving FDA guidance. Whether a 503A pharmacy may compound semaglutide depends on FDA shortage status and other regulatory factors that have shifted over the past 18 months. Halftime Health follows the current framework and only dispenses through licensed clinicians and partner pharmacies.
Disclaimer
This article is educational and is not medical advice. Compounded GLP-1 medications are prepared by state-licensed 503A compounding pharmacies from FDA-approved active pharmaceutical ingredients and are not themselves FDA-approved. GLP-1 therapies are available only with a valid prescription following a licensed clinician evaluation. Clinical outcomes depend on individual factors including baseline health, adherence, diet, and physical activity. Individual results vary. Side effects are common and may include nausea, injection-site reactions, and gastrointestinal symptoms. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
Sources
- FDA. Compounding and the FDA: Questions and Answers.
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism, 2018.
